Details of the Drug

General Information of Drug (ID: DM9NYHT)

Drug Name

LY2787106

Indication

Disease Entry	ICD 11	Status	REF
Anemia	3A00-3A9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Anemia

ICD Disease Classification

3A00-3A9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Hepcidin (HAMP)	DTT	HAMP	5.37E-01	0.18	0.47

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01340976) A Phase 1 Study of LY2787106 in Cancer and Anemia. U.S. National Institutes of Health.
2	A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73.